Bambusa Prices Upsized $169M IPO at $16 a Share, Debuts on Nasdaq Friday
Summary
Bambusa Therapeutics priced an upsized IPO of 10,555,555 shares at $16.00 apiece, raising roughly $168.9 million in gross proceeds before fees, with all shares being offered by Bambusa. The clinical-stage immunology and inflammation biotech also granted underwriters a 30-day option on up to 1,583,333 additional shares. Shares begin trading on the Nasdaq Global Select Market on October 30, 2026 under BBTX, with the offering expected to close November 2. BofA Securities, Evercore ISI, UBS Investment Bank and Cantor are joint book-running managers. The raise funds a pipeline led by BBT001 (IL-4Rα/IL-31 bispecific) in atopic dermatitis and BBT002 (IL-4Rα/IL-5) in Type 2 inflammatory disorders, plus preclinical BBT003 and BBT004. First-day trading will set the real valuation read on the $16 clearing price.
This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.